These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pan B; Lentzsch S Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092 [TBL] [Abstract][Full Text] [Related]
8. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Raza S; Safyan RA; Lentzsch S Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory drugs in AL amyloidosis. Jelinek T; Kufova Z; Hajek R Crit Rev Oncol Hematol; 2016 Mar; 99():249-60. PubMed ID: 26806146 [TBL] [Abstract][Full Text] [Related]
11. [IMiDs in hematology]. Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980 [TBL] [Abstract][Full Text] [Related]
12. [Thalidomide: mechanisms of action and new insights in hematology]. Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258 [TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Holstein SA; McCarthy PL Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024 [TBL] [Abstract][Full Text] [Related]
14. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Leitch HA; Buckstein R; Shamy A; Storring JM Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy. Colley A; Brauns T; Sluder AE; Poznansky MC; Gemechu Y Trends Mol Med; 2024 Aug; 30(8):765-780. PubMed ID: 38821771 [TBL] [Abstract][Full Text] [Related]
16. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Vallet S; Witzens-Harig M; Jaeger D; Podar K Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Castelli R; Cassin R; Cannavò A; Cugno M Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):1-7. PubMed ID: 23153925 [TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma. Srkalovic G; Hussein M Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117 [TBL] [Abstract][Full Text] [Related]